Eli Lilly Strengthens Lead in Obesity Drug Race

By admin June 10, 2026 No comment

featured News Trending

Pharmaceutical giant Eli Lilly has reinforced its dominance in the rapidly growing obesity treatment market after presenting promising trial results for its experimental drug retatrutide. Data shared at the American Diabetes Association conference showed the once-weekly injection could deliver greater weight loss than any obesity drug currently available or under

Novo Nordisk Loses Wegovy-Era Gains

By admin February 24, 2026 No comment

featured News Trending

Shares of Novo Nordisk plunged more than 16%, erasing the remaining gains driven by its blockbuster weight-loss drug Wegovy. The sharp decline followed disappointing trial results for its next-generation obesity treatment CagriSema, which underperformed a rival therapy from Eli Lilly. The drop pushed Novo’s valuation sharply lower, extending a massive fall from its 2024

Obesity Drug Market Outlook Narrows as Prices Fall and Competition Rises

By admin February 2, 2026 No comment

featured News Trending

The long-standing expectation that the global obesity drug market would reach $150 billion within the next decade is becoming less certain as prices for leading GLP-1 treatments from Novo Nordisk and Eli Lilly decline in the United States. Analysts say intensifying competition, the rise of cash-pay consumers, and the prospect of new drugs and generics […]

Pfizer Prepares Sweeter Bid in Intensifying Battle for Metsera

By admin November 6, 2025 No comment

featured News Trending

Pfizer is preparing to raise its offer for obesity drugmaker Metsera after a U.S. judge refused to block rival Novo Nordisk’s $10 billion bid, according to a source. The pharmaceutical giant is scrambling to keep its takeover plans alive as its current merger agreement with Metsera is set to expire at midnight ET without an […]